1. Home
  2. XERS vs HONE Comparison

XERS vs HONE Comparison

Compare XERS & HONE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XERS
  • HONE
  • Stock Information
  • Founded
  • XERS 2005
  • HONE 1917
  • Country
  • XERS United States
  • HONE United States
  • Employees
  • XERS N/A
  • HONE N/A
  • Industry
  • XERS Biotechnology: Pharmaceutical Preparations
  • HONE Major Banks
  • Sector
  • XERS Health Care
  • HONE Finance
  • Exchange
  • XERS Nasdaq
  • HONE Nasdaq
  • Market Cap
  • XERS 500.2M
  • HONE 532.6M
  • IPO Year
  • XERS 2018
  • HONE 2016
  • Fundamental
  • Price
  • XERS $3.47
  • HONE $12.13
  • Analyst Decision
  • XERS Buy
  • HONE Hold
  • Analyst Count
  • XERS 3
  • HONE 1
  • Target Price
  • XERS $4.87
  • HONE $13.00
  • AVG Volume (30 Days)
  • XERS 1.8M
  • HONE 228.7K
  • Earning Date
  • XERS 11-08-2024
  • HONE 01-28-2025
  • Dividend Yield
  • XERS N/A
  • HONE 2.64%
  • EPS Growth
  • XERS N/A
  • HONE N/A
  • EPS
  • XERS N/A
  • HONE 0.27
  • Revenue
  • XERS $187,361,000.00
  • HONE $158,656,000.00
  • Revenue This Year
  • XERS $24.27
  • HONE N/A
  • Revenue Next Year
  • XERS $18.57
  • HONE $9.50
  • P/E Ratio
  • XERS N/A
  • HONE $44.20
  • Revenue Growth
  • XERS 22.72
  • HONE N/A
  • 52 Week Low
  • XERS $1.69
  • HONE $9.16
  • 52 Week High
  • XERS $3.87
  • HONE $14.00
  • Technical
  • Relative Strength Index (RSI)
  • XERS 54.75
  • HONE 34.73
  • Support Level
  • XERS $3.32
  • HONE $11.88
  • Resistance Level
  • XERS $3.57
  • HONE $13.09
  • Average True Range (ATR)
  • XERS 0.18
  • HONE 0.37
  • MACD
  • XERS -0.01
  • HONE -0.10
  • Stochastic Oscillator
  • XERS 42.86
  • HONE 17.99

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

About HONE HarborOne Bancorp Inc.

HarborOne Bancorp Inc is a bank holding company. The company is engaged in providing financial services like accepting deposits, lending loans, online and mobile banking, cash management, credit cards, money market accounts, and wealth management. The Company has two reportable segments: HarborOne Bank and HarborOne Mortgage. The bank provides financial services to individuals and businesses online and through its full-service branches located in Massachusetts and Rhode Island, one limited-service branch, and a commercial lending office in each of Boston, Massachusetts and Providence, Rhode Island.

Share on Social Networks: